论文部分内容阅读
目的 研究甲状腺癌患者大剂量13 1I治疗的有效半衰期及影响因素。方法 入选的甲状腺癌患者共 2 0例 ,其中首次治疗 12例 ,重复治疗 8例。在患者服药后 0～ 9d的相同时间点测量其照射量率。有效半衰期由测量数据经一室模型拟合后算得。结果 首次治疗的有效半衰期为 0 .6 492d ,重复治疗的有效半衰期为 0 .5 12 3d ,两者比较差异有显著性 (P <0 .0 5 )。局部转移与肺部转移相比 ,有效半衰期分别为 0 .4997和 0 .6 10 5d ,差异亦有显著性 (P <0 .0 5 )。结论 甲状腺癌患者大剂量13 1I治疗的有效半衰期与治疗次数及转移部位有关。重复治疗患者应通过药物及其他手段延长有效半衰期 ,以提高疗效。
Objective To study the effective half-life and influential factors of high-dose 131I treatment in patients with thyroid cancer. Methods A total of 20 thyroid cancer patients were enrolled, of whom 12 were for the first time and 8 were for repeated treatment. The patient’s medication 0 ~ 9d after the same time point to measure the exposure rate. The effective half-life is calculated by fitting the measured data to the one-compartment model. Results The effective half-life of the first treatment was 0.6492d, and the effective half-life of the repeat treatment was 0.55-12 3d. There was significant difference between the two (P <0.05). Compared with the lung metastasis, the effective half-lives were 0.4999 and 0.6605, respectively, and the difference was also significant (P <0.05). Conclusions The effective half-life of high-dose 131I treatment in patients with thyroid cancer is related to the number of treatment and metastatic sites. Repeated treatment of patients should extend the effective half-life by drugs and other means to improve the efficacy.